Get the Stockscreener App
11.13
2.11%
-0.23
Alvotech stock is traded at $11.13, with a volume of 25,522.
It is down -2.11% in the last 24 hours and down -10.18% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
See More
Previous Close:
$11.36
Open:
$11.4
24h Volume:
25,522
Relative Volume:
0.17
Market Cap:
$3.41B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-6.0162
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
-6.32%
1M Performance:
-10.18%
6M Performance:
-2.03%
1Y Performance:
-29.44%
1-Day Range:
$11.12
$11.43
1-Week Range:
$11.12
$11.89
52-Week Range:
$9.15
$16.95
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
11.13 | 3.41B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
168.82 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.59 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.94 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.16 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.29 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Pharmaceutical firms launch Stelara biosimilars - Drug Store News
FDA accepts Alvotech, Teva's BLA for proposed Eylea biosimilar - Drug Store News
Is Alvotech (ALVO) the Best Low Price Pharma Stock to Invest In Right Now? - Yahoo Canada Finance
Alvotech (NASDAQ:ALVO) Shares Up 5.5%Time to Buy? - MarketBeat
12 Best Low Price Pharma Stocks To Invest In Right Now - Insider Monkey
Alvotech to Report Full Year Financial Results for 2024 on - GlobeNewswire
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET - The Manila Times
Alvotech Launches SELARSDI Biosimilar in U.S. Market - TipRanks
Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung - GlobeNewswire
When Will Alvotech Reveal Its 2024 Performance? Key Dates for Investors - StockTitan
Teva and Alvotech launch ustekinumab biosimilar injection in US - Yahoo Finance
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US - MSN
Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara - MSN
Alvotech (NASDAQ:ALVO) Shares Down 6.7%Here's What Happened - MarketBeat
Teva and Alvotech gets FDA review acceptance for its proposed biosimilar to Eylea - MSN
Teva, Alvotech Launch SELARSDI, Stelara Biosimilar - Contract Pharma
Teva Pharma and Alvotech launch US biosimilar to J&J’s Stelara - PharmaLive
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - MSN
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - The Korea Bizwire
Teva, Alvotech announces U.S. availability of SELARSDI injection - TipRanks
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara -February 21, 2025 at 06:27 am EST - Marketscreener.com
Alvotech og Teva tilkynna að sala er hafin í Bandaríkjunum - GlobeNewswire
Teva And Alvotech Announce Selarsdi(TM) Injection Now Available In The U.S. -February 21, 2025 at 06:07 am EST - Marketscreener.com
Teva Pharma and Alvotech launch Stelara biosimilar in US -February 21, 2025 at 06:09 am EST - Marketscreener.com
Alvotech Eyeing US Aflibercept Biosimilar Approval This Year With FDA Acceptance - Citeline News & Insights
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea - MSN
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea - Marketscreener.com
Teva and Alvotech advance biosimilar portfolio in USA - The Pharma Letter
FDA accepts BLA for Alvotech’s Eylea biosimilar AVT06 review - World Pharmaceutical Frontiers
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar - Managed Healthcare Executive
Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea (TEVA:NYSE) - Seeking Alpha
FDA Accepts Alvotech’s Eylea Biosimilar for Review - Contract Pharma
Alvotech’s AVT06 Biosimilar Application Accepted by FDA - TipRanks
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept) - Marketscreener.com
US FDA Accepts Alvotech, Teva's Biologics License Application for Eylea Biosimilar - Marketscreener.com
Alvotech and Teva’s BLA filing for AVT06 accepted by FDA - TipRanks
FDA To Review BLA For Alvotech's Proposed Biosimilar To EyleaQuick Facts - Nasdaq
Alvotech and Teva Pharmaceuticals Announce FDA Acceptance of Biologics License Application for AVT06, a Biosimilar Candidate to Eylea - Nasdaq
Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application - Marketscreener.com
Alvotech and Teva Announce Filing Acceptance of U.S. - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - Finansavisen
Alvotech (NASDAQ:ALVO) Now Covered by Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Alvotech (ICSE:ALVO) with Buy Recommendation - Nasdaq
UBS maintains Alvotech stock Buy rating, $18 target By Investing.com - Investing.com Australia
UBS Initiates Coverage of Alvotech (ALVO) with Buy Recommendation - MSN
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):